

DR IRMINGER-FINGER STEPS DOWN FROM THE BARD1 BOARD, CONTINUING AS FOUNDING SCIENTIST

- Dr Irmgard Irminger-Finger steps down from the BARD1 Board to focus on advancing product development of BARD1 autoantibody tests
- Dr Irminger-Finger continues in role of Founding Scientist responsible for providing scientific expertise and technical support to the BARD1 technology programs

Melbourne, Australia, 15 January 2021: BARD1 Life Sciences Limited (ASX:BD1) (**BARD1** or the **Company**) announces that Dr Irmgard Irminger-Finger has stepped down from the board. Dr Irminger-Finger, who resides in Geneva, Switzerland, will continue to provide scientific expertise and technical support to the Company's BARD1 technology programs, the technology she originally invented, with a focus on advancing the development of its BARD1 autoantibody tests.

Dr Irminger-Finger, Founding Scientist, commented: "The COVID-19 pandemic has made it increasingly difficult to contribute as I would like to my directorship duties. With international travel severely restricted I have decided to focus my time and effort on advancing the development of the BARD1 autoantibody program and supporting other BARD1 technology projects from Geneva.

"I am passionate about commercialising the BARD1 autoantibody tests to enable patients to benefit from earlier detection of ovarian, breast and potentially other cancers. I am a significant shareholder of the Company and have great confidence in the future of the Company, the positive contribution it will make to health outcomes, and the commercial value of its technologies and pipeline."

Dr Geoff Cumming, BARD1 Chairman, added: "The Board thanks Dr Irmgard Irminger-Finger for her scientific guidance to the board since 2016 and support her decision to focus her efforts on the BARD1 autoantibody program at this important phase of product development. The Company will continue to benefit from her scientific advice on our strong BARD1 development programs and new research projects going forward."

Authorised by the Company Secretary, Tony Di Pietro.

- ENDS -

COMPANY CONTACTS

Dr Leearne Hinch

CEO

E leearne@bard1.com

M +61 400 414 416

Dr Geoff Cumming

Non-executive Chairman

E geoff.cumming@bard1.com

M +61 417 203 021

ABOUT BARD1 LIFE SCIENCES LTD

BARD1 Life Sciences Ltd (ASX:BD1) (**BARD1** or the **Company**) is a leading Australian diagnostics company with an innovative portfolio of diagnostic technologies and products. The Company is focused on developing and commercialising best-in-class diagnostic solutions for healthcare professionals and patients. The cancer diagnostics portfolio includes the commercialised hTERT test used as an adjunct to urine cytology testing and diagnostic tests in development for ovarian, breast, lung, prostate and pancreatic cancers. For more information on BARD1, see www.bard1.com.

FORWARD LOOKING STATEMENTS

This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may,' 'should,' 'expect,' 'anticipate,' 'estimate,' 'scheduled' or 'continue' or the

negative version of them or comparable terminology. Any forecasts or other forward-looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. The Company does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.